开发一种新型的HER2-CAR单细胞细胞疗法,具有可控制的增殖和增强的抗瘤疗效
Bing Yang1,2, Xiaoxue Wang3, Xundong Wei2
1Peking University Fifth School of Clinical Medicine, Beijing 100730, China.
Chinese medical journal
|January 20, 2024
概括
工程化化学抗原受体单细胞 (CAR-M) 有效向HER2阳性瘤,并增强T细胞透. 这种新的CAR-THP1疗法对组合治疗有前途,改善了抗瘤免疫反应.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 免疫细胞透到瘤中的不足限制了CAR-T细胞治疗的有效性.
- 由于瘤微环境的丰富,CAR-单细胞/巨细胞 (CAR-M) 显示出潜力.
- 开发了一种新的CAR-M来增强T细胞和免疫细胞的透.
研究的目的:
- 构建和评估一种新的仿真抗原受体单细胞 (CAR-M) 疗法.
- 评估CAR-THP1.1的抗瘤疗效和免疫细胞透能力.
- 探索CAR-THP1与其他免疫细胞结合的协同潜力.
主要方法:
- 可诱导的caspase-9 (iCasp9) 和HER2 CAR元素通过lentivirus转移到THP1细胞中.
- 使用流式细胞计,Incucyte和小鼠模型评估自杀效率和抗瘤有效性.
- 转录组测序以分析信号通路和评估与RAK细胞结合的CAR-THP1.
主要成果:
- 一种包含iCasp9,CD3ζ和CD147的新型CAR-THP1证明了受控的增殖和特定的抗瘤疗效.
- CAR-THP1分化为M1表型,弥合先天性和适应性免疫.
- 使用CAR-THP1和RAK细胞的组合疗法通过降解瘤基质并促进T细胞透,提高了治疗效率.
结论:
- CAR-THP1对HER2阳性瘤表现出有效性.
- CAR-THP1显示出与其他免疫细胞结合治疗的显著潜力.
- 这种方法增强了抗瘤免疫反应和免疫细胞透.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527